The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.
This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.
Craig Chepke,1,2 Michael J. Doane,3 Lindsay Jesteadt,4,5 Kristen McCausland,6 Jane Lazar Tucker,6 Gretchen Murphy,3 Anne Marie Morse,7 David T. Plante8
1Excel Psychiatric Associates, P.A., Huntersville, NC, USA; 2Atrium Health, Charlotte, NC, USA; 3Alkermes, Inc., Waltham, MA, USA; 4Sleep Consortium, Inc., West Palm Beach, FL, USA; 5Hypersomnia Foundation, Atlanta, GA, USA; 6IQVIA Quality Metric, Johnston, RI, USA; 7Geisinger Commonwealth School of Medicine, Geisinger Medical Center, Janet Weis Children’s Hospital, Danville, PA, USA; 8University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA
